1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorders (OUD/StUD) R41/42 STTR (RFA-DA-24-038) / R43/44 SBIR (RFA-DA-23-021) is sponsored by National Institute on Drug Abuse (NIDA). These opportunities support the development of therapeutic and diagnostic solutions for opioid and/or stimulant use disorders.
These are SBIR/STTR grants, typically for small businesses, but universities often partner with small businesses for these.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) | Research Funding National Institutes of Health Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD).
Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device.
This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.
Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.
Companion FOA: RFA-DA-23-021 , R43 / R44 Small Business Innovation Research Grants (SBIR) - Phase I/ Small Business Innovation Research Grants (SBIR) - Phase II Letter of Intent Due Date(s): 30 days prior to receipt date Application Due Dates: Aug 15, 2023; Feb 14, 2024; Aug 13, 2024; Feb 14, 2025 RFA-DA-24-038 Expiration Date February 15, 2025 Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Total funding support (direct costs, indirect costs, fee) may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards. Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Small businesses are primary applicants, but universities can be involved through sub-awards or partnerships. Confirm the full requirements in the official notice before applying.
The current listing shows up to $400,000 for Phase I, $3,000,000 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorders (OUD/StUD) R41/42 STTR (RFA-DA-24-038) / R43/44 SBIR (RFA-DA-23-021) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article